Department of Thoracic Oncology Kanagawa Cancer Center, Nakao 1-1-2, Asahi-ku, Yokohama 241-0815, Japan.
Cancer Chemother Pharmacol. 2013 Feb;71(2):345-50. doi: 10.1007/s00280-012-2011-y. Epub 2012 Nov 3.
The standard chemotherapy for Japanese patients with extensive disease of small-cell lung cancer (ED-SCLC) is cisplatin and irinotecan.
Patients with untreated ED-SCLC were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan (CPT) at 50 mg/m(2) on days 1 and 8 every 4 weeks for four cycles.
Twenty-five patients were registered. Nineteen patients were male and six female, with a median age of 64 years (50-79 years). Two patients had a performance status of 2. Nineteen of them were able to receive 4 courses of NP and CPT chemotherapy. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia occurred in 8.0, 68.0, and 36.0 % of patients, respectively. Other grade 3 toxicities were SGOT, hyponatremia, fatigue, vomiting, diarrhea, hypotension, febrile neutropenia, oral hemorrhage, and pneumonia. Grade 4 fatigue occurred in one patient. There was no treatment-related death. The overall response rate was 100 %. The median progression-free and overall survivals were 6.6 and 16.0 months, respectively, and the 2-year survival rate was 28 %.
NP with CPT is effective and safe for patients with ED-SCLC.
广泛期小细胞肺癌（ED-SCLC）日本患者的标准化疗方案是顺铂和伊立替康。
未经治疗的 ED-SCLC 患者接受奈达铂（NP）50mg/m²和伊立替康（CPT）50mg/m²，第 1 天和第 8 天，每 4 周为一个周期，共 4 个周期。
共登记了 25 例患者。19 例为男性，6 例为女性，中位年龄为 64 岁（50-79 岁）。2 例患者的体能状态为 2 分。19 例患者能够接受 4 个周期的 NP 和 CPT 化疗。分别有 8.0%、68.0%和 36.0%的患者出现 3 级或 4 级贫血、中性粒细胞减少和血小板减少。其他 3 级毒性反应包括 SGOT、低钠血症、疲劳、呕吐、腹泻、低血压、发热性中性粒细胞减少、口腔出血和肺炎。1 例患者出现 4 级疲劳。无治疗相关死亡。总缓解率为 100%。中位无进展生存期和总生存期分别为 6.6 个月和 16.0 个月，2 年生存率为 28%。
NP 联合 CPT 治疗 ED-SCLC 患者是有效且安全的。
